Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | GABRP | O00591 | 2/20 | 0.50 |
| ▸ | GABRD | O14764 | 2/20 | 0.50 |
| ▸ | G6PD | P11413 | 2/20 | 0.50 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.50 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.50 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.50 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.50 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.50 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.50 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.50 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.50 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.50 |
| ▸ | GABRE | P78334 | 2/20 | 0.50 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.50 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.50 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.50 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17543941 | 1.00 | CYP3A4 (0.50) | CYP3A4GABRPGABRDG6PDGABRA1 | |
| SCHEMBL10538227 | 1.00 | CYP3A4 (0.50) | CYP3A4GABRPGABRDG6PDGABRA1 | |
| SCHEMBL10538223 | 1.00 | CYP3A4 (0.50) | CYP3A4GABRPGABRDG6PDGABRA1 | |
| SCHEMBL19253170 | 0.81 | ALDH1A1 (0.53) | CYP3A4LMNACYP1A2CYP2C19MEN1 | |
| SCHEMBL10538199 | 0.81 | ALDH1A1 (0.53) | CYP3A4LMNACYP1A2CYP2C19MEN1 | |
| SCHEMBL10538195 | 0.81 | ALDH1A1 (0.53) | CYP3A4LMNACYP1A2CYP2C19MEN1 | |
| SCHEMBL20894876 | 0.79 | GRIN1 (0.57) | — | |
| SCHEMBL19253157 | 0.79 | GRIN1 (0.57) | — | |
| SCHEMBL19733267 | 0.76 | LMNA (0.50) | CYP3A4G6PDLMNACYP1A2CYP2C9 | |
| SCHEMBL10538271 | 0.76 | SHBG (0.51) | CYP3A4MEN1KMT2AAKR1B10AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3260462-B1 | AMPHIPHILIC COMPOUNDS WITH NEUROPROTECTIVE PROPERTIES | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR V V I (CZ) | 2019-04-17 | — | — | EP | disclosed |
| US-10017535-B2 | Amphiphilic compounds with neuroprotective properties | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. (CZ) | 2018-07-10 | — | — | US | disclosed |
| EP-3260462-A1 | AMPHIPHILIC COMPOUNDS WITH NEUROPROTECTIVE PROPERTIES | Ustav Organicke Chemie A Biochemie Av Cr, V.v.i. (CZ) | 2017-12-27 | — | — | EP | disclosed |
| US-20170240588-A1 | AMPHIPHILIC COMPOUNDS WITH NEUROPROTECTIVE PROPERTIES | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. (CZ) | 2017-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170240588-A1 | AMPHIPHILIC COMPOUNDS WITH NEUROPROTECTIVE PROPERTIES | GAP43, GRIN2A, GRIN3A | CYP3A4 2790/4885GABRP 64/4885GABRD 211/4885 |
| US-10017535-B2 | Amphiphilic compounds with neuroprotective properties | GAP43, GRIN2A, GRIN3A | CYP3A4 2790/4885GABRP 64/4885GABRD 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.